Receive instant alerts when news is published about your stocks. Claim your one week free trial for StreetInsider Premium here.
Wilmington, Del.–(Newsfile Corp. – Feb. 3, 2022) – Rigrodsky Law, PA is investigating potential claims against officers and directors of BioMarin Pharmaceutical Inc. (“BioMarin”) (NASDAQ: BMRN) on behalf of shareholders.
On October 25, 2021, a class action lawsuit was filed against BioMarin. The Complaint alleges that between January 13, 2020 and September 3, 2021, the Defendants made materially false and misleading statements regarding BioMarin’s business, operations and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was not as safe as BioMarin led investors to believe; (ii) the safety profile of BMN 307 made it likely that the FDA would suspend the Phearless Phase 1/2 study; (iii) thus, BioMarin exaggerated the clinical and commercial prospects of BMN 307; and (iv) therefore, BioMarin’s public statements were materially false and misleading.
To learn more about this survey and your rights, visit: https://www.rl-legal.com/cases-biomarin-pharmaceutical-inc.
You can also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation toll free at (888) 969-4242 or email@example.com.
Rigrodsky Law, PA, with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms relating to securities fraud and national class actions.
Lawyer advertisement. Previous results do not guarantee a similar result.
Rigrodsky Law, Pennsylvania
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (toll-free)
Fax: (302) 654-7530
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112762